Selective in Biological Technology

Peregrine Pharmaceuticals Licenses Anti-VEGF Antibodies to Affitech

... and commercialize products under Peregrine's selective anti-VEGF intellectual property portfolio, ... an excellent opportunity for both companies. The selective anti-VEGF antibodies we have been jointly ... successfully identified fully human, potent and selective anti-VEGF antibodies as part of a previous ...

Intellikine Completes $51 Million Financing

... classes of proprietary compounds that are potent, selective and druglike inhibitors of PI3K isoforms. The company's most advanced compound, INK128, a selective TORC1/2 inhibitor, has demonstrated efficacy in ... most advanced compound, INK128, a potent and selective TORC1/2 inhibitor with exceptional drug-like ...

Retrospective Analysis of Phase 3 Data Suggest Wyeth's Investigational Compound Bazedoxifene/Conjugated Estrogens Comparable to Placebo on Incidence of Abnormal Mammograms

... Wyeth describes this compound as a tissue selective estrogen complex (TSEC). In a retrospective ... over two years. BZA is an investigational selective estrogen receptor modulator (SERM) under ... About TSEC Wyeth describes the pairing of a selective estrogen receptor modulator (SERM) and one or ...

Abbott Scientists Present a New Approach for Treating Attention-Deficit Hyperactivity Disorder

... present new Phase II data showing that ABT-089, a selective neuronal nicotinic receptor (NNR) agonist, is ... alpha 4 beta 2 NNR Agonist Program ABT-089 is a selective NNR agonist, which targets the alpha 4 beta 2 NNR ... 7 NNR Agonist Program ABT-107 is a potent and selective NNR agonist, which targets the alpha 7 NNR ...

Bionovo Identifies and Describes ER-beta Selective Compounds for the Treatment of Vaginal Dryness

... elucidation of active estrogen receptor beta selective compounds from VG101, Bionovo's drug candidate ... and synthesized three analogues displaying selective estrogen receptor beta activity, which is the ... women. VG101 is a novel estrogen receptor beta selective agonist and unlike currently available ...

VaxGen Issues Rebuttal to MedCap Letter

... exacerbated by MedCap's inaccurate and highly selective use of third party references. MedCap draws on ... MedCap continues this pattern of selective quotation in a further release dated March 20, ... not referenced by MedCap. MedCap's selective use of these third party sources is ...

Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results

... a non-clinical study of SNS-032, a potent and selective inhibitor of cyclin-dependent kinases (CDKs) ... trial of SNS-314, a potent and selective inhibitor of Aurora kinases A, B and C, in ... CLL or multiple myeloma. SNS-314, a potent and selective pan-Aurora kinase inhibitor, is being studied in ...

Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008

... excellent specificity. The high degree of selective targeting seen in the study provides ... confirmed that Peregrine's fully human, selective anti-VEGF antibody R84 was as effective as ... tumor growth in a model of human breast cancer. selective anti-VEGF agents may have potential ...

Anavex 7-1037 reduces rate of cancer tumor growth 69% in pre-clinical studies, compared to currently marketed drug Dacarbazine showing no measurable activity

... addition, ANAVEX 7-1037 has been shown to induce selective apoptosis (programmed cell death) in HCT116 ... results suggested that the compound may be selective against certain cancer types (such as ... for sigma receptors with strong evidence for selective pro-apoptotic, anti-metastatic and low toxicity ...

Astex Drug Candidates to be Featured at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

... 2007 in San Francisco. AT7519 is a potent and selective Cyclin Dependent Kinase (CDK) inhibitor currently ... Phase 1 clinical trials. AT13148 is a potent and selective inhibitor of AKT and certain other AGC kinases, ... 1/2 multi-center clinical trials; - AT13387, a selective inhibitor of Hsp90, for which Astex will ...

Baxter to Launch GARDian(TM), a Groundbreaking Initiative That Helps Provide Continued Access to GAMMAGARD for Current Patients

... GAMMAGARD S/D must not be used in patients with selective IgA deficiency (IgA, 0.05 g/L) where the IgA ... GAMMAGARD S/D must not be used in patients with selective IgA deficiency (IgA < 0.05 g/L) where the IgA ... to Immune Globulin (Human). Patients with severe selective IgA deficiency (IgA < 0.05 g/L) may develop ...

Supelco(R) and MIP Technologies Launch New SPE Product for the Selective Extraction of NSAIDs From Environmental Water

... of a new molecularly imprinted polymer, SPE product, SupelMIP(TM), for the selective extraction of non-steroidal anti-inflammatory drugs (NSAIDs). ... separations'. The Company has the ability to produce MIPs and other selective polymers from laboratory to pilot scale and is well placed to develop ...

Proteolix to Present Carfilzomib Clinical Data During the 2009 ASCO Annual Meeting

... Study PX-171-007: A Phase Ib/II study of carfilzomib (CFZ), a selective proteasome inhibitor, in patients with selected advanced ... inhibitors, including a selective, oral proteasome inhibitor and a selective immunoproteasome inhibitor. For additional information on Proteolix, ...

Ausio Pharmaceuticals to Present at Bio(R) 2009

... S-equol, a soy metabolite, and acts as a nonsteroidal, nonhormonal, selective estrogen receptor beta (ER beta) agonist. The safety profile of AUS-131 in ... of individuals. AUS-131 is a first-in-class, nonsteroidal, nonhormonal, selective ER beta agonist that has the potential to provide therapeutic benefits ...

Neurocrine Biosciences Reports First Quarter 2009 Results

... Neurocrine and GSK has identified multiple unique high affinity and selective antagonists for the CRF1 receptor that are currently in clinical ... of nerve impulses between neurons. Neurocrine identified a highly selective VMAT2 inhibitor that is effective in regulating the levels of dopamine ...

AEterna Zentaris Presents Two Posters on its PI3K Inhibitor Compound, AEZS-126, at AACR Annual Meeting

... Poster #3706 Entitled, "In vitro profiling of the potent and selective PI3K inhibitor, AEZS-126", I. Seipelt, M. Gerlach, L. Blumenstein, G. ... of low molecular weight pyridopyrazine compounds as highly potent and selective inhibitors of class I PI3Ks. Presented here, are the key in vitro ...

Alexandria Real Estate Equities, Inc. Announces Pricing of Public Follow-On Offering of 7,000,000 Shares of Common Stock

... capital and other corporate purposes, including the repayment of debt and selective redevelopment and development of existing or new life science properties. ... cluster formation through the ownership, operation, management and selective redevelopment, development and acquisition of properties containing ...

Bionovo Announces 2008 Highlights and Year-End Financial Results

... in the journal Cancer Biology and Treatment , described the powerful and selective mechanism of action for BZL101 in cancer tumors. Another study was ... describing the structural elucidation of active estrogen receptor beta selective compounds from VG101, Bionovo's drug candidate for vaginal atrophy. This ...

Global Biopharmaceutical Leader in Peptide Research Expands Commitment in San Diego/U.S. With New R&D Facility and Ready-To-Market Prostate Cancer Treatment Degarelix

... barusiban (FE 200440), an oxytocin receptor antagonist; FE 202158, a selective V1a receptor agonist; FE 200665 (a.k.a. CR665), a first generation ... peripherally-selective kappa opioid receptor agonist; and FE 202767, a selective oxytocin receptor agonist. More information is available at ...

New Biologic STELARA(TM) Receives Approval in Europe for Treatment of Moderate to Severe Plaque Psoriasis

... the United States. Important Safety Information STELARA is a selective immunosuppressant and may have the potential to increase the risk of ... infection prior to initiating treatment with STELARA. STELARA is a selective immunosuppressant. Immunosuppressive agents have the potential to ...

Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year

... quarter reflects a strong finish to an important transitional year. Our selective investments in research and development, enhanced sales channels, and ... with the previously disclosed strategy for growth and expansion via highly selective acquisitions. The transaction is expected to be slightly accretive to ...

Sangamo BioSciences Presents Data at ICAAC Demonstrating 'In Vivo' Protection Against HIV Infection by CCR5-ZFN Therapeutic

... Preclinical Animal Data Demonstrates selective Survival Advantage of ZFN-Treated Immune Cells after HIV Infection and ... data suggest that, in the presence of HIV, the ZFN-modified cells have a selective advantage allowing them to evade infection and destruction leaving them ...

CeNeRx BioPharma Completes $15 Million Series B Financing

... been achieving in our clinical and preclinical programs." Tyrima is a selective and reversible member of a novel class of drugs known as RIMAs, or ... market, and we are in early discussions with potential partners for our selective cannabinoids, which are showing promise preclinically in a number of ...

GlaxoSmithKline and Cellzome Announce Major Strategic Alliance

... access to Cellzome's significant expertise in identifying and developing selective kinase inhibitors and its proprietary Kinobeads(TM) technology which, by ... signaling events with a central role in many inflammatory responses and selective inhibitors offer a different approach to therapeutic intervention in ...

Pharmos Corporation Announces That it Will Cease Operations in Israel

... Iselin, New Jersey. The research programs in Israel are the CB2 receptor selective library of compounds, including preclinical development of PRS-639,058 ... of synthetic cannabinoid compounds with a focus on CB2 receptor selective agonists. Various CB2-selective compounds from Pharmos' pipeline have ...

Halozyme Therapeutics Reports 2008 Second Quarter Financial Results

... with the chemotherapeutic agent alone. The effects of PEGPH20 were selective to prostate tumors producing hyaluronan, consistent with the selective reduction of tumor interstitial fluid pressure. Treatment with PEGPH20 ...

SuperGen Reports 2008 Second Quarter Financial Results

... PIM kinase inhibitors. SGI-1776 was identified as a potent and selective inhibitor of the PIM kinases, inducing apoptosis and cell cycle ... SGI-1776 was identified as an orally available, potent and selective inhibitor of the PIM kinases. SGI-1776 induces cell cycle arrest, ...

Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMed's Selective Kinase Inhibitor

... the evaluation of pharmacokinetic parameters. ENMD-2076 is a novel, selective kinase inhibitor with potent activity against Aurora A and tyrosine ... clinical trial sites are now enrolling and treating patients with our selective kinase inhibitor. We believe that this product candidate has substantial ...

Lorus Therapeutics presents new findings for the anticancer drugs LOR-253 and LOR-2040

... the potential treatment of these cancers with LOR-253, which has shown selective and potent anticancer activity in animal models of non-small cell lung ... About LOR-253 LOR-253 is a small molecule compound that has shown selective and potent antitumor activity in a variety of human cancers, including ...

SGX Presents Preclinical MET Data at AACR

... (AACR) in San Diego. The poster entitled "SGX523, a potent and exquisitely selective inhibitor of the HGF receptor tyrosine kinase (MET), inhibits growth of ... Inhibitors 1 in Exhibit Hall B-F. SGX's MET program comprises potent, selective ATP-competitive MET inhibitors, from which a number of drug-like compounds ...

MedImmune Presents Data Highlighting its Progressive Oncology Portfolio at Annual Meeting of the American Association For Cancer Research

... April 12 from 4:15 - 4:40 p.m. in Ballroom 20D. -- IPI-504, a selective Inhibitor of Hsp90, Exhibits Potent Anti-Tumor Activity Against ... April 15 from 1:00 - 5:00 p.m. in Exhibit Hall B-F. -- IPI-504, a selective Hsp90 Inhibitor is Biologically Active and Tolerated in Combination ...

Pharmacyclics Announces Multiple Presentations at the American Association for Cancer Research Annual Meeting

... An additional presentation describes the activity of an HDAC-8 selective inhibitor that has demonstrated anti-inflammatory properties in ... Cell Cycle Inhibitors Poster presentation: The histone deacetylase-8 selective inhibitor PCI-34051 displays both anti-neoplastic and ...

Option to Develop Exelixis Compound Exercised By Genentech

... option to further develop and commercialize Exelixis' compound XL518, a selective and potent inhibitor of MEK, which is currently in a phase 1 clinical ... (Abstract #C209). In vitro analyses indicate that XL518 is a potent and selective non-ATP-competitive inhibitor of MEK1. Inhibition of MEK activity by XL518 ...

Stonegate Report About Unigene Laboratories Inc.

... increase sales of calcitonin-based products - Bisphosphonate therapies and selective estrogen receptor modulators (SERMS) are the current market leaders in the ... calcitonin, calcium, vitamin D, testosterone, parathyroid hormone and selective estrogen receptor modulators (SERMs). The results indicated that ...

Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Women's Cancer

... trial in patients with ovarian cancer. SNS-032, Sunesis' potent and selective inhibitor of cyclin-dependent kinases 2, 7 and 9, is being evaluated in a ... chronic lymphocytic leukemia and multiple myeloma. SNS-314, a potent and selective pan-Aurora kinase inhibitor, is being studied in a Phase 1 dose-escalating ...

NicOx Initiates Two Large ABPM Studies for Naproxcinod in Hypertensive Patients with Osteoarthritis

... to be a variation between different products, with ibuprofen and the selective COX-2 inhibitors bringing about greater increases than non- selective drugs, such as naproxen. However, all existing products have been ...

Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results

... -- Presented phase 1 data for second-generation MET inhibitor XL184, selective PI3K inhibitor XL147 and dual PI3K/mTOR inhibitor XL765, and phase 2 ... NSCLC in October. -- Presented encouraging phase 1 data for XL019, our selective inhibitor of JAK2, in December. -- Filed investigational new drug ...

Phase 1 Studies Show Promise of QuatRx's Novel Compound, Sobetirome, for Lowering LDL Cholesterol Levels

... Results from two separate Phase 1 studies show sobetirome, a selective thyroid hormone receptor beta agonist, reduced levels of low-density ... was generally well tolerated in both studies. Sobetirome is a new selective thyroid hormone receptor beta agonist that may activate reverse ...

Schering-Plough Announces Sugammadex New Drug Application Filed in Japan

... Health, Labour and Welfare (MHLW) seeking marketing approval for its novel selective relaxant binding agent (SRBA), sugammadex. Sugammadex is specifically ... on November 19, 2007. About Sugammadex Sugammadex is a novel selective relaxant binding agent (SRBA) under development by Organon, a part of ...

Phase I Safety and Tolerability Study With EVT 302 Successfully Completed

... basis for further clinical development. EVT 302, a reversible and highly selective inhibitor of MAO-B in development for smoking cessation, was investigated ... subjects. About EVT 302 EVT 302 is an orally active, potent, highly selective and reversible inhibitor of MAO-B in development for smoking cessation. ...